SEC filings and other documents

Guidance for FY2026 targets $47.5–$48.5M revenue and 15–18% growth, driven by innovation and expansion.

Q2 revenue up 18% to $12M, positive net income, and raised gross margin guidance.

Strong recurring revenue and pipeline expansion drive double-digit growth in SC drug delivery.

Record Q1 revenue growth of 22% and strong international expansion set the stage for 2026.

2025 revenue rose 22% to $41.1M, with strong growth, profitability, and new leadership ahead.

International expansion, new drugs, and product launches drive >20% growth and margin gains.

Q3 revenue up 27% year-over-year; guidance raised as international and SCIG growth accelerates.

Sustained 20%+ growth fueled by new drugs, global expansion, and strong recurring revenue.

Record Q2 revenue and raised guidance highlight strong growth, led by international expansion.

Q1 revenue up 18% year-over-year; guidance raised on strong core and international growth.

2024 revenue up 18% to $33.6M, gross margin 63.4%, net loss cut to $6.1M.